Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Antibiot (Tokyo) ; 70(2): 122-129, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27381521

RESUMEN

Enterobacter cloacae is a Gram-negative bacterium associated with high morbidity and mortality in intensive care patients due to its resistance to multiple antibiotics. Currently, therapy against multi-resistant bacteria consists of using colistin, in spite of its toxic effects at higher concentrations. In this context, colistin-resistant E. cloacae strains were challenged with lower levels of colistin combined with other antibiotics to reduce colistin-associated side effects. Colistin-resistant E. cloacae (ATCC 49141) strains were generated by serial propagation in subinhibitory colistin concentrations. After this, three colistin-resistant and three nonresistant replicates were isolated. The identity of all the strains was confirmed by MALDI-TOF MS, VITEK 2 and MicroScan analysis. Furthermore, cross-resistance to other antibiotics was checked by disk diffusion and automated systems. The synergistic effects of the combined use of colistin and chloramphenicol were observed via the broth microdilution checkerboard method. First, data here reported showed that all strains presented intrinsic resistance to penicillin, cephalosporin (except fourth generation), monobactam, and some associations of penicillin and ß-lactamase inhibitors. Moreover, a chloramphenicol and colistin combination was capable of inhibiting the induced colistin-resistant strains as well as two colistin-resistant clinical strains. Furthermore, no cytotoxic effect was observed by using such concentrations. In summary, the data reported here showed for the first time the possible therapeutic use of colistin-chloramphenicol for infections caused by colistin-resistant E. cloacae.


Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacología , Colistina/farmacología , Farmacorresistencia Bacteriana Múltiple , Enterobacter cloacae/efectos de los fármacos , Pared Celular/efectos de los fármacos , ADN Bacteriano , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , ARN Bacteriano
2.
Biochim Biophys Acta ; 1848(11 Pt B): 3078-88, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25724815

RESUMEN

Resistant bacterial infections are a major health problem in many parts of the world. The major commercial antibiotic classes often fail to combat common bacteria. Although antimicrobial peptides are able to control bacterial infections by interfering with microbial metabolism and physiological processes in several ways, a large number of cases of resistance to antibiotic peptide classes have also been reported. To gain a better understanding of the resistance process various technologies have been applied. Here we discuss multiple strategies by which bacteria could develop enhanced antimicrobial peptide resistance, focusing on sub-cellular regions from the surface to deep inside, evaluating bacterial membranes, cell walls and cytoplasmic metabolism. Moreover, some high-throughput methods for antimicrobial resistance detection and discrimination are also examined. This article is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.


Asunto(s)
Péptidos Catiónicos Antimicrobianos/metabolismo , Bacterias/metabolismo , Infecciones Bacterianas/metabolismo , Farmacorresistencia Bacteriana , Animales , Antibacterianos/uso terapéutico , Péptidos Catiónicos Antimicrobianos/uso terapéutico , Bacterias/efectos de los fármacos , Bacterias/patogenicidad , Infecciones Bacterianas/microbiología , Infecciones Bacterianas/prevención & control , Membrana Celular/metabolismo , Pared Celular/metabolismo , Ensayos Analíticos de Alto Rendimiento , Interacciones Huésped-Patógeno , Humanos , Pruebas de Sensibilidad Microbiana/métodos , Viabilidad Microbiana , Transducción de Señal
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA